Durata Therapeutics

Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.

Durata Therapeutics, Inc.
IndustryPharmaceutical industry
FateAcquired by Actavis (now Allergan)
Founded2009 (2009)
DefunctNovember 17, 2014 (November 17, 2014)
HeadquartersMorristown, New Jersey

History

On December 21, 2009, the company acquired Vicuron Pharmaceuticals and its drug candidate, dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer and commenced operations.[1]

On April 19, 2011, the company initiated Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.[2]

In 2012, the company moved its global headquarters from Morristown to Chicago and received $2 million in tax credits.[3]

On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.[4]

References
  1. "Newly Formed Durata Therapeutics Acquires Pfizer's Vicuron Subsidiary" (Press release). PR Newswire. December 21, 2009.
  2. "Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections" (Press release). Business Wire. April 19, 2011.
  3. Frost, Peter (November 14, 2012). "Durata biotech moving headquarters to Chicago". Chicago Tribune.
  4. "Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer" (Press release). PR Newswire. November 17, 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.